Barclays’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-1,900
| Closed | -$21K | – | 7508 |
|
|
2018
Q4 | $21K | Buy |
+1,900
| New | +$26.4K | ﹤0.01% | 5886 |
|
|
2018
Q3 | – | Sell |
-1,600
| Closed | -$33K | – | 7568 |
|
|
2018
Q2 | $33K | Sell |
1,600
-14,000
| -90% | -$300K | ﹤0.01% | 5912 |
|
|
2018
Q1 | $283K | Buy |
15,600
+1,100
| +8% | +$18.3K | ﹤0.01% | 4511 |
|
|
2017
Q4 | $202K | Buy |
14,500
+13,300
| +1,108% | +$180K | ﹤0.01% | 4682 |
|
|
2017
Q3 | $22K | Sell |
1,200
-1,500
| -56% | -$25.1K | ﹤0.01% | 5758 |
|
|
2017
Q2 | $46K | Sell |
2,700
-3,600
| -57% | -$54.8K | ﹤0.01% | 5407 |
|
|
2017
Q1 | $84K | Buy |
6,300
+1,400
| +29% | +$21.9K | ﹤0.01% | 5015 |
|
|
2016
Q4 | $74K | Buy |
4,900
+2,100
| +75% | +$27.7K | ﹤0.01% | 4947 |
|
|
2016
Q3 | $33K | Buy |
2,800
+2,600
| +1,300% | +$30.6K | ﹤0.01% | 5226 |
|
|
2016
Q2 | $2K | Sell |
200
-1,600
| -89% | -$16.5K | ﹤0.01% | 6015 |
|
|
2016
Q1 | $16K | Buy |
+1,800
| New | +$19.4K | ﹤0.01% | 5319 |
|
|
2015
Q4 | – | Sell |
-500
| Closed | -$8K | – | 6836 |
|
|
2015
Q3 | $8K | Sell |
500
-6,200
| -93% | -$127K | ﹤0.01% | 5886 |
|
|
2015
Q2 | $147K | Buy |
6,700
+3,500
| +109% | +$69.7K | ﹤0.01% | 4378 |
|
|
2015
Q1 | $48K | Sell |
3,200
-20,700
| -87% | -$269K | ﹤0.01% | 5309 |
|
|
2014
Q4 | $287K | Buy |
23,900
+10,100
| +73% | +$115K | ﹤0.01% | 4351 |
|
|
2014
Q3 | $152K | Sell |
13,800
-2,500
| -15% | -$28.5K | ﹤0.01% | 4981 |
|
|
2014
Q2 | $196K | Sell |
16,300
-16,700
| -51% | -$197K | ﹤0.01% | 4834 |
|
|
2014
Q1 | $363K | Buy |
33,000
+7,200
| +28% | +$122K | ﹤0.01% | 4223 |
|
|
2013
Q4 | $439K | Buy |
25,800
+10,000
| +63% | +$168K | ﹤0.01% | 4230 |
|
|
2013
Q3 | $221K | Sell |
15,800
-28,600
| -64% | -$438K | ﹤0.01% | 4945 |
|
|
2013
Q2 | $669K | Buy |
+44,400
| New | +$586K | ﹤0.01% | 3878 |
|
Barclays's MNTA Position: Q4 2020 in Review
Barclays sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 248,815 shares — an estimated $13.1M sold.
Barclays first reported a position in MNTA in Q2 2013 and held it in 29 quarters. The position peaked at $13.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Barclays reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Barclays sold 248,815 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $13.1M.
- Barclays first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Barclays's Momenta Pharmaceuticals, Inc. position peaked at $13.1M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.